On August 4, Moderna, Inc. rose 5.28% in regular trading, trading at $56.5/share, with turnover of $41.76 million. The rally was driven by a convergence of positive catalysts including multiple analyst price target upgrades and the approaching PDUFA review date for the company's fifth product.

On the institutional front, UBS raised its price target on Moderna from $45 to $50 while maintaining a Neutral rating, and Bank of America Global Research raised its target from $38 to $40. Both upgrades signal improving sentiment toward the stock in the near term. Meanwhile, the company's fifth product, Mflusiva, faces a critical FDA PDUFA review date on August 5, with market expectations for approval continuing to build. The optimism is underpinned by the FDA advisory committee's unanimous 9-0 vote in favor of Moderna's seasonal flu vaccine candidate mRNA-1010.

Additionally, Moderna's Q2 results reported on July 31 showed a narrower-than-expected loss of $1.97 per share versus consensus estimates of approximately $2.01-$2.10, with revenue of $145 million beating the $102.9 million estimate.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)